Description
LXH254 is a type II RAF inhibitor.
Product Unit Size | Cost | Quantity | Stock |
---|
LXH254 is a type II RAF inhibitor.
Cas No. | 1800398-38-2 |
---|---|
Purity | ≥99% |
Formula | C25H25F3N4O4 |
Formula Wt. | 502.49 |
IUPAC Name | N-[3-[2-(2-hydroxyethoxy)-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]-2-(trifluoromethyl)pyridine-4-carboxamide |
Synonym | Naporafenib |
Appearance | White powder |
Store Temp | -20°C |
---|---|
Ship Temp | Ambient |
Info Sheet |
---|
Monaco K, Delach S, Yuan J, et al. LXH254, a potent and selective ARAF-sparing inhibitor of BRAF and CRAF for the treatment of MAPK-driven tumors. Clin Cancer Res. 2021 Apr 1;27(7):2061-2073. PMID: 33355204
Park S, Kim T, Cho S, et al. Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells. Cancer Lett. 2020 Dec 28;495:135-144. PMID: 32979462
Endogenous neuropeptide hormone, lowers extrace...
Fluoroquinolone; topoisomerase IV and bacterial...
c-Raf activator, tyrosine kinase inhibitor.
Indirect activator of STING signaling
GABA-A antagonist.
Triazole; 14-α demethylase inhibitor, potentia...
NSAID; COX-1/2 inhibitor.
Triterpene saponin originally found in Bolboste...
Diphenylmethane, inhibits secretion of cortisol...
Fluoroquinolone; topoisomerase IV and bacterial...
Synthetis peptide, melanocortin analog; MCR ago...
Alkaloid found in Securinega; potential GABA-A ...
Immunodominant peptide fragment of PLP, used to...
BHA derivative.
α-glucosidase inhibitor, potential GLP-1 agoni...
Protease substrate.
Topoisomerase II inhibitor, RPA modulator.
mTORC1 inhibitor.
Dual inhibitor of p70S6K and Akt.
Cysteine-ITC conjugate, antioxidant.